[Myo-inositol in the treatment of polycystic ovary syndrome].
Presentation of a comprehensive body of knowledge on the role of insulin sensitizer myo-inositol in the treatment of polycystic ovary syndrome (PCOS). Review article. Institute for the Care of Mother and Child, Prague. An overview of publishing data. Polycystic ovary syndrome is the most common cause of ovarian dysfunction and anovulatory infertility in women. The insulin resistance occurs very frequently as a part of PCOS. This paper reviews the literature documenting the effectiveness of insulin sensitizer myo-inositol in the treatment of ovarian dysfunction, symptoms of hyperandrogenism and wide complex of symptoms of metabolic syndrome. Six randomized controlled trials provides evidence of a positive effect of myo-inositol to normalize ovarian function, improve laboratory and clinical manifestations of hyperandrogenism and insulin resistance. The myo-inositol treatment has been demonstrated as a safe method of PCOS management.